FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076095420> ?p ?o ?g. }

• W2076095420 endingPage "241" @default.
• W2076095420 startingPage "238" @default.
• W2076095420 abstract "Since C-reactive protein (CRP) plays a role in the pathogenesis of cardiovascular disease and is a marker and predictor of cardiovascular disease, it could be expected that lowering of CRP levels would prevent the development of the disease and its complications [ [1] Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006; 24: 33-50 Crossref PubMed Scopus (213) Google Scholar ]. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits advanced glycation end product (AGE)-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma (PPAR-γ) activation [ [2] Yoshida T. Yamagishi S. Nakamura K. et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia. 2006; 49: 3094-3099 Crossref PubMed Scopus (113) Google Scholar ]. Indeed, chronic treatment with telmisartan significantly reduced the elevated CRP levels in diabetic rats [ [3] Goyal B.R. Mesariya P. Goyal R.K. Mehta A.A. Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Mol Cell Biochem. 2008; 314: 123-131 Crossref PubMed Scopus (46) Google Scholar ], and telmisartan administration significantly reduced serum CRP levels in high-fat diet-treated rats [ [4] Xu X. Yin X. Feng W. Li G. Wang D. Tu L. Telmisartan protects against insulin resistance by attenuating inflammatory response in rats. J Huazhong Univ Sci Technolog Med Sci. 2011; 31: 317-323 Crossref PubMed Scopus (6) Google Scholar ]. Additionally, after 12 months of treatment with telmisartan, plasma high sensitivity CRP (hsCRP) levels decreased in hypertensive patients with type 2 diabetes mellitus [ [5] Wago T. Yoshimoto T. Akaza I. et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res. 2010; 33: 796-801 Crossref PubMed Scopus (27) Google Scholar ]. Although telmisartan therapy would be expected to reduce hsCRP levels in a clinical setting, results of a number of randomized controlled trials have been inconclusive and no meta-analysis of them has been conducted to date. To determine whether telmisartan therapy reduces hsCRP levels, we performed the first meta-analysis of randomized controlled trials." @default.
• W2076095420 created "2016-06-24" @default.
• W2076095420 creator A5006435222 @default.
• W2076095420 creator A5011740260 @default.
• W2076095420 creator A5050498443 @default.
• W2076095420 creator A5051671230 @default.
• W2076095420 creator A5058828145 @default.
• W2076095420 date "2012-04-01" @default.
• W2076095420 modified "2023-10-14" @default.
• W2076095420 title "Effects of telmisartan on C-reactive protein levels: A meta-analysis of randomized controlled trials" @default.
• W2076095420 cites W1971552275 @default.
• W2076095420 cites W1973275724 @default.
• W2076095420 cites W1976167638 @default.
• W2076095420 cites W1992464903 @default.
• W2076095420 cites W1993489156 @default.
• W2076095420 cites W1997355903 @default.
• W2076095420 cites W2003194113 @default.
• W2076095420 cites W2005112720 @default.
• W2076095420 cites W2010651929 @default.
• W2076095420 cites W2012575420 @default.
• W2076095420 cites W2023314157 @default.
• W2076095420 cites W2033451677 @default.
• W2076095420 cites W2044257849 @default.
• W2076095420 cites W2044390537 @default.
• W2076095420 cites W2049677309 @default.
• W2076095420 cites W2052443593 @default.
• W2076095420 cites W2068453888 @default.
• W2076095420 cites W2075648762 @default.
• W2076095420 cites W2085427506 @default.
• W2076095420 cites W2087554021 @default.
• W2076095420 cites W2088685081 @default.
• W2076095420 cites W2104340251 @default.
• W2076095420 cites W2115742160 @default.
• W2076095420 cites W2122295798 @default.
• W2076095420 cites W2127934772 @default.
• W2076095420 cites W2132915402 @default.
• W2076095420 cites W2133502874 @default.
• W2076095420 cites W2134578903 @default.
• W2076095420 cites W2136114093 @default.
• W2076095420 cites W2136948246 @default.
• W2076095420 cites W2139638393 @default.
• W2076095420 cites W2155952282 @default.
• W2076095420 cites W4243857162 @default.
• W2076095420 doi "https://doi.org/10.1016/j.ijcard.2012.01.104" @default.
• W2076095420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22353440" @default.
• W2076095420 hasPublicationYear "2012" @default.
• W2076095420 type Work @default.
• W2076095420 sameAs 2076095420 @default.
• W2076095420 citedByCount "10" @default.
• W2076095420 countsByYear W20760954202012 @default.
• W2076095420 countsByYear W20760954202014 @default.
• W2076095420 countsByYear W20760954202015 @default.
• W2076095420 countsByYear W20760954202016 @default.
• W2076095420 countsByYear W20760954202019 @default.
• W2076095420 countsByYear W20760954202022 @default.
• W2076095420 crossrefType "journal-article" @default.
• W2076095420 hasAuthorship W2076095420A5006435222 @default.
• W2076095420 hasAuthorship W2076095420A5011740260 @default.
• W2076095420 hasAuthorship W2076095420A5050498443 @default.
• W2076095420 hasAuthorship W2076095420A5051671230 @default.
• W2076095420 hasAuthorship W2076095420A5058828145 @default.
• W2076095420 hasConcept C104317684 @default.
• W2076095420 hasConcept C126322002 @default.
• W2076095420 hasConcept C127561419 @default.
• W2076095420 hasConcept C134018914 @default.
• W2076095420 hasConcept C170493617 @default.
• W2076095420 hasConcept C185592680 @default.
• W2076095420 hasConcept C187345961 @default.
• W2076095420 hasConcept C2776914184 @default.
• W2076095420 hasConcept C2779716603 @default.
• W2076095420 hasConcept C2781195455 @default.
• W2076095420 hasConcept C55493867 @default.
• W2076095420 hasConcept C555293320 @default.
• W2076095420 hasConcept C71924100 @default.
• W2076095420 hasConcept C84393581 @default.
• W2076095420 hasConcept C98274493 @default.
• W2076095420 hasConceptScore W2076095420C104317684 @default.
• W2076095420 hasConceptScore W2076095420C126322002 @default.
• W2076095420 hasConceptScore W2076095420C127561419 @default.
• W2076095420 hasConceptScore W2076095420C134018914 @default.
• W2076095420 hasConceptScore W2076095420C170493617 @default.
• W2076095420 hasConceptScore W2076095420C185592680 @default.
• W2076095420 hasConceptScore W2076095420C187345961 @default.
• W2076095420 hasConceptScore W2076095420C2776914184 @default.
• W2076095420 hasConceptScore W2076095420C2779716603 @default.
• W2076095420 hasConceptScore W2076095420C2781195455 @default.
• W2076095420 hasConceptScore W2076095420C55493867 @default.
• W2076095420 hasConceptScore W2076095420C555293320 @default.
• W2076095420 hasConceptScore W2076095420C71924100 @default.
• W2076095420 hasConceptScore W2076095420C84393581 @default.
• W2076095420 hasConceptScore W2076095420C98274493 @default.
• W2076095420 hasIssue "2" @default.
• W2076095420 hasLocation W20760954201 @default.
• W2076095420 hasLocation W20760954202 @default.
• W2076095420 hasOpenAccess W2076095420 @default.
• W2076095420 hasPrimaryLocation W20760954201 @default.
• W2076095420 hasRelatedWork W2020449916 @default.
• W2076095420 hasRelatedWork W2034583712 @default.

• next